AU2020411507A1 - Methods and compositions for inhibition of dihydroorotate dehydrogenase - Google Patents

Methods and compositions for inhibition of dihydroorotate dehydrogenase Download PDF

Info

Publication number
AU2020411507A1
AU2020411507A1 AU2020411507A AU2020411507A AU2020411507A1 AU 2020411507 A1 AU2020411507 A1 AU 2020411507A1 AU 2020411507 A AU2020411507 A AU 2020411507A AU 2020411507 A AU2020411507 A AU 2020411507A AU 2020411507 A1 AU2020411507 A1 AU 2020411507A1
Authority
AU
Australia
Prior art keywords
compound
halogen
hydrogen
alkyl
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020411507A
Other languages
English (en)
Inventor
Chad E. Bennett
John C. Byrd
Ola A. ELGAMAL
Thomas E. Goodwin
Erin HERTLEIN
Sandip Madhukar VIBHUTE
Tyler Aron WILSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State Innovation Foundation
Hendrix College
Original Assignee
Ohio State Innovation Foundation
Hendrix College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation, Hendrix College filed Critical Ohio State Innovation Foundation
Publication of AU2020411507A1 publication Critical patent/AU2020411507A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2020411507A 2019-12-26 2020-12-26 Methods and compositions for inhibition of dihydroorotate dehydrogenase Pending AU2020411507A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962953708P 2019-12-26 2019-12-26
US62/953,708 2019-12-26
PCT/US2020/067065 WO2021134042A1 (en) 2019-12-26 2020-12-26 Methods and compositions for inhibition of dihydroorotate dehydrogenase

Publications (1)

Publication Number Publication Date
AU2020411507A1 true AU2020411507A1 (en) 2022-07-14

Family

ID=76575157

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020411507A Pending AU2020411507A1 (en) 2019-12-26 2020-12-26 Methods and compositions for inhibition of dihydroorotate dehydrogenase

Country Status (6)

Country Link
US (1) US20240018108A1 (https=)
EP (1) EP4081215A4 (https=)
JP (1) JP7800865B2 (https=)
AU (1) AU2020411507A1 (https=)
CA (1) CA3165512A1 (https=)
WO (1) WO2021134042A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020412805A1 (en) * 2019-12-26 2022-07-14 Hendrix College Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-CD38 therapeutic agent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680299A (en) * 1984-04-30 1987-07-14 E.I. Du Pont De Nemours And Company 2-phenyl-4-quinolinecarboxylic acids and pharmaceutical compositions thereof
US8710079B2 (en) 2010-04-23 2014-04-29 National Health Research Institutes Quinoline compounds and their use for treating viral infection
WO2019246603A1 (en) 2018-06-22 2019-12-26 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase
AU2020412805A1 (en) * 2019-12-26 2022-07-14 Hendrix College Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-CD38 therapeutic agent

Also Published As

Publication number Publication date
JP2023512413A (ja) 2023-03-27
JP7800865B2 (ja) 2026-01-16
EP4081215A1 (en) 2022-11-02
CA3165512A1 (en) 2021-07-01
KR20220132538A (ko) 2022-09-30
WO2021134042A1 (en) 2021-07-01
US20240018108A1 (en) 2024-01-18
EP4081215A4 (en) 2024-01-10
CN115361948A (zh) 2022-11-18

Similar Documents

Publication Publication Date Title
US11999697B2 (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase
CA3161373A1 (en) Compositions and methods for substituted 7-(piperazin-1-yl)pyrazolo[1,5-a]pyrimidine analogs as inhibitors of kras
US12295939B2 (en) Substituted benzothiophene analogs as selective estrogen receptor degraders
JP7736275B2 (ja) 抗ｃｄ３８治療剤と組み合わせたジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物
US20240018108A1 (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase
US20230089524A1 (en) Compositions for use in the inhibition of dihydroorotate dehydrogenase
US20230109418A1 (en) Compositions for use for the inhibition of dihydroorotate dehydrogenase
US20250122185A1 (en) Compositions and methods comprising substituted n-(2-chloro-6-methylphenyl)-2-((6-(6-membered heterocycloalkyl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide analogues
KR102956115B1 (ko) 디하이드로오로테이트 데하이드로게나제를 억제하는 방법 및 조성물
CN115361948B (en) Methods and compositions for inhibiting dihydroorotate dehydrogenase
HK40084674A (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase
WO2025227007A1 (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase